NTRK1 and central nervous system cancer: Although glioma patients are not routinely tested for NTRK1 rearrangements, if ongoing clinical trials with entrectinib confirm the encouraging survival data obtained in our preclinical model, it will be important to develop simple assays, based on RT–PCR or interphase FISH, to identify NTRK1 fusions in brain tumours.